Anlon Healthcare Limited AHCL NSEPHARMA
Company Overview
Anlon Healthcare Limited manufactures and sells active pharmaceutical ingredients in India and internationally. The company also offers bulk drugs; advanced pharmaceutical intermediates; nutraceutical API products; and drug intermediates. It also manufactures loxoprofen sodium dihydrate, ketoprofen, and dexketoprofen trometamol products for pain management and anti-inflammatory therapies. Anlon Healthcare Limited was incorporated in 2013 and is based in Rajkot, India.
Why Investors Should Care
Return on capital employed stands at 17.4%.
Net profit has compounded at 69.8% per year over the last five years.
Revenue has grown at a 15.1% CAGR over the past five years.
Operating margin of 16.6% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.17.
Recent Developments
- Mar 2026 Revenue of ₹171.97 Cr (+43.0% YoY); net profit ₹28.51 Cr.
- Trailing 12 Months Year-on-year growth — revenue +163.0%, earnings +39.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 15.1%, profit CAGR 69.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 15.07% |
| 1 Year: | 163.00% |
Compounded Profit Growth
| 5 Years: | 69.84% |
| 1 Year: | 38.97% |
Stock Price Performance
| 1 Year: | +179.41% |
| 6 Months: | +61.50% |
| 3 Months: | +72.36% |
| 1 Month: | +11.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)46.98 · Neutral
P/E of 37.69 is above the sector median of 36.43 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 15.1% over 5 years.
- Profit CAGR of 69.8% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 29.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AHCL Anlon Healthcare Limited NSEPHARMA | 25.63 | 37.69 | ₹1,362.27 Cr | 0.00% | 17.36% | 12.38% | 15.07% | 69.84% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,745.10 | 34.62 | ₹4.19 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,190.00 | 83.58 | ₹2.44 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,553.80 | 72.74 | ₹1.73 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,117.30 | 24.90 | ₹1.11 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 631.35 | 164.41 | ₹1.09 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,600.00 | 52.32 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,012.50 | 99.48 | ₹1.09 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,314.00 | 31.51 | ₹1.06 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 9.36 Cr | 48.93 Cr | 52.20 Cr | 35.58 Cr | 50.89 Cr |
| Cost of Revenue | 5.65 Cr | 27.63 Cr | 32.96 Cr | 20.07 Cr | 27.85 Cr |
| Gross Profit | 3.71 Cr | 21.30 Cr | 19.24 Cr | 15.51 Cr | 23.04 Cr |
| Operating Expenses | 3.14 Cr | 4.94 Cr | 5.96 Cr | 3.52 Cr | 8.04 Cr |
| Operating Income | 57.66 L | 16.36 Cr | 13.29 Cr | 11.99 Cr | 15.00 Cr |
| EBITDA | 59.55 L | 17.23 Cr | 13.77 Cr | 12.54 Cr | 1,445.16 Cr |
| Interest Expense | 88.66 L | 91.42 L | 86.61 L | 1.58 Cr | 57.07 L |
| Pretax Income | -29.11 L | 15.49 Cr | 12.45 Cr | 10.61 Cr | 1,444.30 Cr |
| Tax Provision | 2.19 Cr | 1.16 Cr | 3.13 Cr | 5.46 Cr | -3.37 Cr |
| Net Income | -2.49 Cr | 16.65 Cr | 9.32 Cr | 5.15 Cr | 10.50 Cr |
| Diluted EPS | -0.05 | 0.31 | 0.18 | 0.11 | 0.23 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 112.88 Cr | 66.58 Cr | 120.29 Cr | 171.97 Cr |
| Cost of Revenue | - | 88.40 Cr | 36.45 Cr | 74.59 Cr | 105.10 Cr |
| Gross Profit | - | 24.47 Cr | 30.13 Cr | 45.70 Cr | 66.86 Cr |
| Operating Expenses | - | 13.41 Cr | 16.29 Cr | 15.26 Cr | 20.87 Cr |
| Operating Income | - | 11.06 Cr | 13.84 Cr | 30.43 Cr | 45.99 Cr |
| EBITDA | - | 12.65 Cr | 15.72 Cr | 32.38 Cr | 47.77 Cr |
| Interest Expense | - | 3.79 Cr | 4.08 Cr | 3.72 Cr | 3.74 Cr |
| Pretax Income | - | 6.99 Cr | 9.75 Cr | 26.89 Cr | 42.51 Cr |
| Tax Provision | - | 1.17 Cr | 9.40 L | -6.37 Cr | -13.42 Cr |
| Net Income | - | 5.82 Cr | 9.66 Cr | 20.52 Cr | 28.51 Cr |
| Diluted EPS | -0.00 | 0.11 | 0.18 | 0.39 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 111.55 Cr | 128.00 Cr | 181.30 Cr | 373.97 Cr |
| Current Assets | - | 85.81 Cr | 100.70 Cr | 158.48 Cr | 308.26 Cr |
| Cash & Equivalents | - | 62.36 L | 2.27 Cr | 1.45 Cr | 4.37 Cr |
| Inventory | - | 26.97 Cr | 41.71 Cr | 50.26 Cr | 113.16 Cr |
| Receivables | - | 43.81 Cr | 38.73 Cr | 75.00 Cr | 103.68 Cr |
| Total Liabilities | - | 104.17 Cr | 106.97 Cr | 100.88 Cr | 119.17 Cr |
| Current Liabilities | - | 43.55 Cr | 50.10 Cr | 60.05 Cr | 107.57 Cr |
| Long Term Debt | - | 58.18 Cr | 54.25 Cr | 38.36 Cr | 6.09 Cr |
| Total Debt | - | 70.32 Cr | 81.25 Cr | 66.55 Cr | 43.65 Cr |
| Total Equity | - | 7.37 Cr | 21.03 Cr | 80.42 Cr | 230.23 Cr |
| Shares Outstanding | - | 53.15 Cr | 53.15 Cr | 53.15 Cr | 53.15 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -2.85 Cr | -3.23 Cr | -22.55 Cr | -79.44 Cr |
| Investing Cash Flow | - | -33.49 L | -3.37 Cr | 2.79 Cr | -36.34 Cr |
| Financing Cash Flow | - | 2.27 Cr | 8.25 Cr | 18.94 Cr | 118.69 Cr |
| Capital Expenditure | - | -37.22 L | -3.53 Cr | -52.93 L | -36.47 Cr |
| Free Cash Flow | - | -3.22 Cr | -6.76 Cr | -23.08 Cr | -115.91 Cr |
| Net Change in Cash | - | -91.87 L | 1.65 Cr | -82.50 L | 2.92 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 21.7% | 45.3% | 38.0% | 38.9% |
| Operating Margin % | - | 9.8% | 20.8% | 25.3% | 26.7% |
| Net Margin % | - | 5.2% | 14.5% | 17.1% | 16.6% |
| ROE % | - | 78.9% | 45.9% | 25.5% | 12.4% |
| ROCE % | - | 16.3% | 17.8% | 25.1% | 17.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AHCL
Most Active Stocks, September 21, 2026 at 12:00 PM - HDFC Sky
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5Tc0F2WXJpVmp0SzEzQ0pCZnB1V2syT3M0Sy1qMjViSmFTWEU1TkREc1E2cmotRnZxdC1fMUVlbjUtalBCal9wWElQd1VjakxCUEF6cVhFX1dDTWtCdUlyNFh0WXpaUnRwUHBsZ1VHcXlrdzlzTWo5Y0V3?oc=5" target="_blank">Mos…
Anlon Healthcare's (NSE:AHCL) Profits May Not Reveal Underlying Issues - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQV2lkMFVMRlZvVXRIbGdJUmIzWURmakhobUpGQW42dTVUR3NMTlFaT1laY1pURjVOSV9QaXVLeUVMbjd4dXFPQklJSlZkNnhoZy12Y2ZOVmNCUmdra0xBdjJrSUprRDJKVUNIbWVVa2pKaWZFazhrS1pkbml1cDlQYVJUTG92VWNsdkFlYz…
Did this recently-listed smallcap stock really crash 90% in one day? Here's why you should ignore the plun - The Economic Times
<a href="https://news.google.com/rss/articles/CBMiiwJBVV95cUxQbnpiTHBvVWIxTThVdG1HOXlQRGcwS3NrOXVadEJ0YnlVdFpFaTFoRTRCQWtQaGRmZGtZRDdyT2k4dlJ1RkNaV1Vwd29hUG9ERElOZXRnTlQyRXZ0M0N6Y0lIOVRNVTQtLTY4cEdLZVljdUJZNjh1aE84ZTRsUmxKaU4wTlc1V1JmenUwUW…
Anlon Healthcare (AHCL.NS) Climbs 7.47% to ₹24.61 as Stock Approaches Key Resistance - Safe Entry Stocks - https://www.siam.in/
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQNjhJYzFVNlI1U2VwQ1U5eEpneXZCNmg1N1N1R1RJQ0xaNElLRnBHRmZrS0JiRVZGMDlQNzVQSElPemUzNTlwd2hDdzZZU3BtSmhsN1VfNGE2SHlCNHVWeHRwVWdOd05LUy0zNmJGMVV6UDdtUTlEQnlCR19yMHl0Vk56dS14ZVpLODRBSD…
AHCL Stock Price and Chart — NSE:AHCL - TradingView
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1heGxyZ0VuSFZzUW9YYjNsNVVCM2lhSzR4NEJ5YzZncG5WN2F0b0V5UVpETGZWUDJrUmJweHhiaGFjYmhjOEpCRHZONW9HaVV3amY3bXdvWl8?oc=5" target="_blank">AHCL Stock Price and Chart — NSE:AHCL</a> &…
ANLON HEALTHCARE Upper Circuit Today: Price, Data and Peers - Univest
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFAwTHU0RVJsaUVoOW5aaExWdkRBbFhCRkFzSlZZQmdjdFpiaFZ3YTlUVTJ1ZU44VWxrQWJPRy1ndEtJNUhFbFNmRUtQMzlGYXNmNjREQWlWUnFZd2NsX0ZsYktETXhtSlVCZ0RBdXRlZ1hydzlzdTZDdS13?oc=5" target="_blank">ANL…
AHCL — Frequently Asked Questions
What is the current share price of Anlon Healthcare Limited (AHCL)?
As of 2026-10-23 04:58 IST, Anlon Healthcare Limited (AHCL) trades at ₹25.63 on NSE. Its 52-week range is ₹9.10 to ₹36.39.
What is the market capitalisation of AHCL?
Anlon Healthcare Limited (AHCL) has a market capitalisation of ₹1,362.27 Cr on NSE.
What is the P/E ratio of AHCL?
AHCL trades at a trailing price-to-earnings (P/E) ratio of 37.69. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 5.50.
What is the return on equity (ROE) of AHCL?
AHCL has a return on equity (ROE) of 12.38%. Its return on capital employed (ROCE) is 17.36%.
Is AHCL a good stock to buy?
This page provides a data-driven analysis of Anlon Healthcare Limited (AHCL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.